GenomeDx has an efficient and growing development pipeline aimed at addressing key clinical questions in urological cancers.
The company’s first test, Decipher®, is a transformative genomic test that provides a direct measure of the true biological risk of metastatic prostate cancer independent of PSA and other clinical risk factors. Decipher is intended for intermediate and high-risk patients following radical prostatectomy, a significant patient population consisting of over 100,000 procedures in the United States each year.
We’re committed to rapid discovery and the development of tests that have a significant impact on clinical practice and patient care. Our comprehensive clinical program is currently made up of multiple discovery and validation studies in prostate and other urologic cancers.